Business
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted
About this update from Arbutus Biopharma Corporation
[{"type":"text","content":"AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100 IU/ml in 75% of treated subjects, and increased HBV-specific immune responses in 3/5 evaluable subjects AB-729 resulted in decreases in HBV RNA and all HBsAg isoforms demonstrating broad target engagement AB-729 dosed for 48 weeks continued to demonstrate a favorable safety and tolerability profile AB-836 pre-clinical data suggest the potential for increased efficacy and an enhanced resistance profile relative to previous generation capsid inhibitors Conference Call and Webcast Scheduled for 8:00 AM ET, Monday, June 28th, 2021 WARMINSTER, Pa., June 26, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced the presentation of five abstracts at the European Association for the Study of the Liver (EASL) International Liver CongressTM (ILC). The abstracts included an oral late-breaker presentation (Presentation LBO-2764) by Professor Man-Fung Yuen, D.Sc., M.D., Ph.D., Deputy Head of Department, Chief of Division of Gastroenterology and Hepatology, Master of Lap Chee, University of Hong Kong, and lead investigator of AB-729’s Phase 1a/1b clinical trial, titled, “Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression.” As presented by Professor Yuen, AB-729 continues to demonstrate robust mean HBsAg reduction across all doses and dosing intervals with a favorable safety and tolerability profile, followed by a sustained plateau phase. Mean (range) change in HBsAg with repeat dosing of AB-729: VisitCohort EAB-729 60 mg Q4WⱡCohort FAB-729 60 mg Q8WCohort I AB-729 90 mgQ8Wp valuebetweenCohortsWeek 16-1.44 (-0.71 to -1.95)-1.39 (-1.61 to -1.08)-1.63 (-0.89 to -2.44)p ≥ 0.4Week 24-1.84 (-0.99 to -2.31)-1.57 (-1.24 to -2.01)-1.79 (-1.22 to -2.46)p ≥ 0.2Week 32-1.84 (-0.94 to -2.36)-1.68 (-1.37 to -2.15)---p = 0.5Week 40-1.84(-0.88 to -2.47)-1.78*(-1.40 to -2.14)---p = 0.7Week 44-1.81* (-0.93 to -2.43)-1.87* (-1.32 to -2.34) [N=6]---p = 0.8Week 48-1.89* ...